MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced will present at the Piper Sandler 35th Annual Healthcare Conference, taking place November 28-30 in New York, NY.
Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Tuesday, November 28 at 2:30pm ET, and management will participate in one-on-one meetings with investors during the conference.
The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available on the Events section of NeuroPace’s Investor website at https://investors.neuropace.com/news-and-events/events.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.18 |
Daily Change: | 0.23 2.10 |
Daily Volume: | 27,869 |
Market Cap: | US$333.720M |
December 04, 2024 December 03, 2024 November 12, 2024 November 04, 2024 August 13, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB